A Oliver Sartor

Summary

Affiliation: Tulane University
Country: USA

Publications

  1. pmc Potential synergistic implications for stromal-targeted radiopharmaceuticals in bone-metastatic prostate cancer
    Oliver Sartor
    Department of Medicine, Tulane Medical School, New Orleans, LA 70115, USA
    Asian J Androl 13:366-8. 2011
  2. doi request reprint Beyond Just Androgen Deprivation Therapy: Novel Therapies Combined With Radiation
    Oliver Sartor
    Tulane Cancer Center, Tulane Medical School, New Orleans, LA Electronic address
    Semin Radiat Oncol 27:87-93. 2017
  3. pmc Independent data monitoring committees: an update and overview
    Oliver Sartor
    Department of Medicine, Tulane University School of Medicine, New Orleans, LA Department of Urology, Tulane University School of Medicine, New Orleans, LA Electronic address
    Urol Oncol 33:143-8. 2015
  4. doi request reprint Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
    Oliver Sartor
    Tulane Cancer Center, New Orleans, LA, USA Electronic address
    Lancet Oncol 15:738-46. 2014
  5. pmc Unmet needs in the prediction and detection of metastases in prostate cancer
    Oliver Sartor
    Tulane Cancer Center, New Orleans, Louisiana 70112, USA
    Oncologist 18:549-57. 2013
  6. doi request reprint Abiraterone and its place in the treatment of metastatic CRPC
    Oliver Sartor
    Department of Medicine, Tulane Medical School, Box SL 42, 1430 Tulane Avenue, New Orleans, LA 70112, USA
    Nat Rev Clin Oncol 10:6-8. 2013
  7. pmc Implications of the prostate intervention versus observation trial (PIVOT)
    Oliver Sartor
    Departments of Medicine and Urology, TulaneUniversity School of Medicine, New Orleans, LA 70112, USA
    Asian J Androl 14:803-4. 2012
  8. doi request reprint Targeted radio-nuclide therapy of skeletal metastases
    Oliver Sartor
    Dept of Medicine, Tulane University School of Medicine, New Orleans, LA 70112, USA
    Cancer Treat Rev 39:18-26. 2013
  9. doi request reprint Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC)
    A Oliver Sartor
    Department of Medicine, Tulane University School of Medicine, New Orleans, LA 70115, USA
    BJU Int 110:328-35. 2012
  10. doi request reprint Evaluating localized prostate cancer and identifying candidates for focal therapy
    A Oliver Sartor
    Department of Medicine, Harvard Medical School, Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Urology 72:S12-24. 2008

Detail Information

Publications47

  1. pmc Potential synergistic implications for stromal-targeted radiopharmaceuticals in bone-metastatic prostate cancer
    Oliver Sartor
    Department of Medicine, Tulane Medical School, New Orleans, LA 70115, USA
    Asian J Androl 13:366-8. 2011
    ..Combination therapies will be required to substantially improve survival for men with castrate-resistant metastatic prostate cancer and we hypothesize that bone-targeted radiopharmaceuticals will play an important role in this process...
  2. doi request reprint Beyond Just Androgen Deprivation Therapy: Novel Therapies Combined With Radiation
    Oliver Sartor
    Tulane Cancer Center, Tulane Medical School, New Orleans, LA Electronic address
    Semin Radiat Oncol 27:87-93. 2017
    ..Clinical trials with radiation and novel forms of therapy are the key to progress, and newer adaptive clinical trial designs may allow such progress to occur faster...
  3. pmc Independent data monitoring committees: an update and overview
    Oliver Sartor
    Department of Medicine, Tulane University School of Medicine, New Orleans, LA Department of Urology, Tulane University School of Medicine, New Orleans, LA Electronic address
    Urol Oncol 33:143-8. 2015
    ..Interim monitoring of safety and efficacy data is an integral part of modern clinical trials...
  4. doi request reprint Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
    Oliver Sartor
    Tulane Cancer Center, New Orleans, LA, USA Electronic address
    Lancet Oncol 15:738-46. 2014
    ..We assessed the effect of radium-223 compared with placebo in patients with castration-resistant prostate cancer and bone metastases...
  5. pmc Unmet needs in the prediction and detection of metastases in prostate cancer
    Oliver Sartor
    Tulane Cancer Center, New Orleans, Louisiana 70112, USA
    Oncologist 18:549-57. 2013
    ....
  6. doi request reprint Abiraterone and its place in the treatment of metastatic CRPC
    Oliver Sartor
    Department of Medicine, Tulane Medical School, Box SL 42, 1430 Tulane Avenue, New Orleans, LA 70112, USA
    Nat Rev Clin Oncol 10:6-8. 2013
    ..We place these data in the context of earlier disease states and other novel agents and explore practical issues concerning the future use of abiraterone...
  7. pmc Implications of the prostate intervention versus observation trial (PIVOT)
    Oliver Sartor
    Departments of Medicine and Urology, TulaneUniversity School of Medicine, New Orleans, LA 70112, USA
    Asian J Androl 14:803-4. 2012
    ..10 ng ml-1 or Gleason scores of 7 or higher. This important study underscores the benefits of observation for those with ‘low risk’ prostate cancer and the potential benefits of surgery for those in higher risk categories...
  8. doi request reprint Targeted radio-nuclide therapy of skeletal metastases
    Oliver Sartor
    Dept of Medicine, Tulane University School of Medicine, New Orleans, LA 70112, USA
    Cancer Treat Rev 39:18-26. 2013
    ..Lastly, we discuss potential advances in combining BSR with bisphosphonates and/or chemotherapy and emphasize the feasibility of repeated dosing...
  9. doi request reprint Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC)
    A Oliver Sartor
    Department of Medicine, Tulane University School of Medicine, New Orleans, LA 70115, USA
    BJU Int 110:328-35. 2012
    ..The prospects for successful treatment of patients with CRPC have developed considerably so that these patients may soon have a reasonable expectation of therapeutic efficacy and meaningful extension of their lives...
  10. doi request reprint Evaluating localized prostate cancer and identifying candidates for focal therapy
    A Oliver Sartor
    Department of Medicine, Harvard Medical School, Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Urology 72:S12-24. 2008
    ....
  11. doi request reprint The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer
    Oliver Sartor
    Department of Medicine, Tulane University, New Orleans, Louisiana 70115, USA
    Urology 75:623-9. 2010
    ..This article describes the design of the COMPARE Registry, together with patient characteristics and prostate cancer management at enrolment...
  12. doi request reprint Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone
    Oliver Sartor
    Dana Farber Cancer Institute, Boston, MA, USA
    Clin Genitourin Cancer 7:E90-2. 2009
    ..We hypothesized that SRDA5 inhibition in combination with ketoconazole would mitigate progression after treatment with ketoconazole alone...
  13. pmc Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space
    A Oliver Sartor
    Department of Medicine, Tulane University School of Medicine, 1430 Tulane Ave, SL 42, New Orleans, LA 70115, USA
    J Hematol Oncol 4:18. 2011
    ..g., MDV3100), as well as other agents, are awaited with interest and may further expand the treatment choices for this difficult-to-manage population of patients...
  14. doi request reprint Prostate cancer. Saturation biopsy does not accurately localize tumors
    Oliver Sartor
    Departments of Urology and Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, SL 42 New Orleans, LA 70112, USA
    Nat Rev Urol 7:479-80. 2010
    ..research efforts would perhaps be better focused on identifying which patients require treatment for clinically localized prostate cancer in the first place...
  15. doi request reprint Combination therapy: Abiraterone prolongs survival in metastatic prostate cancer
    Oliver Sartor
    Department of Medicine and Urology, Tulane Cancer Center, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA
    Nat Rev Clin Oncol 8:515-6. 2011
    ..The survival gain observed in this pivotal trial is accomplished with few adverse events and conclusively demonstrates that patients with castration levels of serum testosterone remain sensitive to additional hormonal manipulation...
  16. doi request reprint Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer
    Oliver Sartor
    Tulane Medical School New Orleans, LA, USA
    Clin Genitourin Cancer 8:23-8. 2010
    ..This trial was pivotal for the FDA's approval of the new drug application for cabazitaxel. This review focuses on both the pre-clinical and clinical development of cabazitaxel...
  17. ncbi request reprint Saposin C stimulates growth and invasion, activates p42/44 and SAPK/JNK signaling pathways of MAPK and upregulates uPA/uPAR expression in prostate cancer and stromal cells
    Shahriar Koochekpour
    Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, 533 Bolivar Street, CSRB 4 17, New Orleans, LA 70112, USA
    Asian J Androl 7:147-58. 2005
    ..In addition, we tested whether saposin C can activate p42/44 and stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK) signal transduction pathways of the mitogen-activated protein kinase (MAPK) superfamily...
  18. doi request reprint Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect
    Robert W Ross
    Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 112:1247-53. 2008
    ..The purpose of this study was to compare predictive factors for the efficacy of androgen deprivation therapy (ADT) in men with hormone-sensitive prostate cancer (HSPC) either with (M+) or without (M-) metastases...
  19. doi request reprint Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer
    Robert W Ross
    Dana Farber Cancer Institute, Dana 710 C, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:842-7. 2008
    ..Androgen-deprivation therapy (ADT) is the most common and effective systemic therapy for advanced prostate cancer. We hypothesized that germline genetic variation in the androgen axis would improve the efficacy of ADT...
  20. pmc Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy
    Toni K Choueiri
    Dana Farber Cancer Institute Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Cancer 115:981-7. 2009
    ....
  21. doi request reprint Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    BJU Int 101:308-12. 2008
    ..To evaluate the efficacy of docetaxel/carboplatin (DC)-based chemotherapy as first- and second-line chemotherapy for patients with hormone-refractory prostate cancer (HRPC)...
  22. ncbi request reprint Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design
    Oliver Sartor
    Tulane Cancer Center, New Orleans, Louisiana, USA
    Can J Urol 16:4806-12. 2009
    ....
  23. ncbi request reprint Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain
    Oliver Sartor
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Cancer 109:637-43. 2007
    ..The purpose of the analysis was to assess the safety and efficacy of repeated doses of Sm-153 in patients with metastatic bone pain...
  24. pmc Evaluation of 8q24 and 17q risk loci and prostate cancer mortality
    Kathryn L Penney
    Department of Epidemiology, Harvard School of Public Health, Harvard University, Cambridge, Massachusetts, USA
    Clin Cancer Res 15:3223-30. 2009
    ..We investigated whether the 8q24 and 17q risk variants are associated with clinical variables as well as prostate cancer mortality...
  25. ncbi request reprint Prostate specific antigen (PSA) may be a poor marker for progression of prostate cancer after treatment with a combination of chemo-hormonal therapies
    Oliver Sartor
    Stanley Scott Cancer Center, New Orleans, Louisiana, USA
    J La State Med Soc 160:99-100. 2008
    ..1 ng/mL. We hypothesize that patients with early stage prostate cancer treated with combinations of androgen deprivation and chemotherapy may be at high risk for this unusual pattern of relapse...
  26. pmc Saposin C promotes survival and prevents apoptosis via PI3K/Akt-dependent pathway in prostate cancer cells
    Tae Jin Lee
    Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, 533 Bolivar Street, CSRB 4 17, New Orleans, LA 70112, USA
    Mol Cancer 3:31. 2004
    ..The biological significances of saposin C and prosaposin in prostate cancer are not known...
  27. pmc Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes
    Bo Ying Bao
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Prostate 68:839-48. 2008
    ..We investigated mechanisms controlling the differential expression of UGT2B15 and B17 in response to androgen treatments...
  28. ncbi request reprint Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Haber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    BJU Int 96:783-6. 2005
    ....
  29. ncbi request reprint Amplification and overexpression of prosaposin in prostate cancer
    Shahriar Koochekpour
    Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
    Genes Chromosomes Cancer 44:351-64. 2005
    ....
  30. ncbi request reprint Unexpected response of hormone-refractory prostate cancer to treatment with an antileukemic chemotherapy regimen
    Navjeet Gandhok
    Stanley S Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Urology 64:807-9. 2004
    ..Autopsy showed minimal evidence of prostate cancer, localized to the prostate...
  31. ncbi request reprint Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer
    Oliver Sartor
    Louisiana State University Medical Center, New Orleans, Louisiana, USA
    Urology 63:940-5. 2004
    ..A Phase III randomized trial was designed to assess the effectiveness of samarium-153 (153Sm)-lexidronam for palliation of bone pain in patients with hormone-refractory prostate cancer...
  32. ncbi request reprint Relationships between reverse transcriptase-polymerase chain reaction for prostate specific antigen, survival, and various prognostic laboratory factors in patients with hormone refractory prostate cancer
    Navjeet K Gandhok
    Department of Medicine, Louisiana State University School of Medicine, and Stanley S Scott Cancer Center, New Orleans, LA 70112, USA
    Urol Oncol 23:163-7. 2005
    ..or=11 g/dL) remained statistically significant (P=0.019), indicating that RT-PCR had no independent association with survival after controlling for hemoglobin status in this study...
  33. pmc Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426)
    A Oliver Sartor
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 112:2393-400. 2008
    ..This study was designed to examine antiandrogen withdrawal effects within the context of a large multi-institutional prospective trial...
  34. pmc Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer
    Mary Ellen Taplin
    Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02115, USA
    Clin Cancer Res 15:7099-105. 2009
    ....
  35. ncbi request reprint Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA)
    A Oliver Sartor
    Tulane Cancer Center, New Orleans, LA Akershus University Hospital, Lorenskog, Norway Haukeland University Hospital, Bergen, Norway Centre for Cancer Research and Cell Biology, Queen s University, Belfast, Ireland Radiumhospitalet, Oslo, Norway Hospital Kochova, Chomutov, Czech Republic Centrum Onkologii Instytut im Sklodowskiej Curie, Warsaw, Poland Christie Hospital, Manchester, United Kingdom Centrallasarettet Växjö, Vaxjo, Sweden Norrlands University Hospital, Umea, Sweden Ullevål University Hospital, Oslo, Norway Karolinska Universitettsjukhuset, Stockholm, Sweden Mount Vernon Hospital Cancer Centre, Middlesex, United Kingdom St Olavs Hospital, Trondheim, Norway Cancer Research UK Clinical Trials Unit, Institute for Cancer Studies, Birmingham, United Kingdom Clatterbridge Centre for Oncology, Wirral, United Kingdom Comprehensive Cancer Centers of Nevada, Las Vegas, NV Algeta ASA, Oslo, Norway Bayer HealthCare Pharmaceuticals
    J Clin Oncol 30:9. 2012
    ..The primary endpoint was OS; secondary endpoints included skeletal-related events (SREs)...
  36. ncbi request reprint Radioisotopic treatment of bone pain from metastatic prostate cancer
    Oliver Sartor
    Department of Hematology Oncology, Louisiana State University School of Medicine, Room 459, 533 Bolivar, New Orleans, LA 70112, USA
    Curr Oncol Rep 5:258-62. 2003
    ..Contraindications to administration of current bone-seeking radioisotopes include substantial degrees of renal insufficiency or bone marrow suppression...
  37. ncbi request reprint Substantial activity of mitoxantrone and paclitaxel in a heavily pre-treated metastatic bladder cancer patient
    Kellie D Schmeeckle
    Division of Hematology Oncology, Stanley Scott Cancer Center, New Orleans, LA, USA
    J La State Med Soc 160:17-8. 2008
    ..The patient's bladder cancer responded dramatically from a clinical, biochemical, and radiographic perspective...
  38. doi request reprint Radiation for bone metastases
    Daniel J Bourgeois
    Tulane Medical School, New Orleans, Los Angeles and USA
    Curr Opin Support Palliat Care 5:227-32. 2011
    ..To synopsize the current state-of-the-art for radiation and treatment of painful bone metastases with a focus on prostate cancer...
  39. ncbi request reprint Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population
    Timothy Gilligan
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Prostate Cancer 3:98-103. 2004
    ..This study confirms earlier reports that black men have shorter CAG repeat lengths than reported white and Asian populations. We did not find an increased risk of prostate cancer among black men with fewer CAG repeats...
  40. ncbi request reprint Endpoints in prostate cancer clinical trials
    Oliver Sartor
    Stanley S Scott Cancer Center, Louisiana State University School of Medicine, New Orleans, Louisiana 70112, USA
    Urology 60:101-7; discussion 107-8. 2002
    ..Prospective randomized trials with adequate follow-up time and the assessment of clinically meaningful endpoints will offer the best opportunity to evaluate the effectiveness of various interventions used in this disease...
  41. ncbi request reprint An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer
    Oliver Sartor
    Louisiana State University School of Medicine, New Orleans, Louisiana, USA
    Urology 62:319-23. 2003
    ..To investigate the safety, efficacy, and pharmacokinetics of a new 4-month subcutaneous depot of leuprolide acetate in patients with prostate cancer...
  42. pmc Berberine suppresses androgen receptor signaling in prostate cancer
    Jing Li
    Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, New Orleans, LA 70112, USA
    Mol Cancer Ther 10:1346-56. 2011
    ..This study is the first to show that berberine suppresses AR signaling and suggests that berberine, or its derivatives, presents a promising agent for the prevention and/or treatment of prostate cancer...
  43. ncbi request reprint Eligard: leuprolide acetate in a novel sustained-release delivery system
    Oliver Sartor
    Stanley S Scott Cancer Center, Louisiana State University School of Medicine, New Orleans, Louisiana 70112, USA
    Urology 61:25-31. 2003
    ..Additional studies with these novel formulations are warranted...
  44. ncbi request reprint Incidence of reduced penis size among men with recurrent prostate cancer previously treated with surgery, radiation plus androgen deprivation, or radiation alone
    Arti Parekh
    Department of Radiation Oncology, Dana Farber Cancer Institute Brigham and Women s Cancer Center Harvard Medical School, Boston, MA University of Connecticut, Storrs, CT Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute Brigham and Women s Hospital, Harvard Medical School, Boston, MA Division of Urologic Surgery and Center for Surgery and Public Health, Brigham and Women s Hospital Harvard Medical School, Boston, MA South Carolina College of Pharmacy and the Hollings Cancer Center, Charleston, SC Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH Departments of Medicine and Urology, Tulane University, New Orleans, LA Eisai Pharmaceuticals, Woodcliff Lake, NJ
    J Clin Oncol 30:38. 2012
    ..38 Background: The relative incidence of reduced penis size across prostate cancer treatment modalities is not well-known...
  45. pmc Cytokine genetic polymorphisms and prostate cancer aggressiveness
    Jovanny Zabaleta
    Department of Pediatrics and Stanley S Scott Cancer Center, Louisiana State University Health Sciences Center, Clinical Sciences Research Building, New Orleans, LA 70112, USA
    Carcinogenesis 30:1358-62. 2009
    ..With limited sample size, the results from this study suggest that SNPs in cytokine genes may be associated with PCa aggressiveness. More extensive studies are warranted to validate our findings...
  46. ncbi request reprint Prosaptide TX14A stimulates growth, migration, and invasion and activates the Raf-MEK-ERK-RSK-Elk-1 signaling pathway in prostate cancer cells
    Shahriar Koochekpour
    Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA
    Prostate 61:114-23. 2004
    ..g., TX14A). The expression and function of prosaposin in prostate cancer is not known...
  47. ncbi request reprint An unusual case of sepsis with both Vibrio vulnificus and Enterococcus casseliflavus
    Bhagat Saumya
    Department of Medicine, Tulane Medical School, New Orleans, LA, USA
    J La State Med Soc 162:153-4, 156-7. 2010
    ..Warming trends in US weather and in particular warming trends in the coastal marshes where oysters are grown and harvested may create less seasonal variation and higher rates of Vibrio infection...